智通财经10月9日讯（记者 林坚）长鑫科技发布辅导进展第一期公告。公告末尾来自保荐机构的辅导人 员密密实实的签字，很是令人吃惊——中金公司、中信建投联合担任辅导机构这单项目，共有34人签 字。 不得不说，在多位资深投行人士眼中，如此庞大的阵容都是比较罕见的情形。 图为长鑫存储辅导工作进展情况报告内文。 今年7月7日，长鑫存储启动上市辅导，目前为期两个月的第一期辅导已经结束，辅导小组成员情况如 下： 中金公司辅导小组成员：吴迪、刘飞峙、魏先勇、刘剑峰、胡璇、田桂宁、熊峰、余朝辉、 叶建冬、杨妍、李开洲、刘馨蔚、吴家腾、于宁、杨箭宇、杨森、张文、赵善军，共18人。 其中，杨森、张文、赵善军为新增辅导人员。 中信建投辅导小组成员：董军峰、廖小龙、黄亚颖、胡家荣、谌泽昊、谭谷、汪鹏飞、梁 文、周岱岳、吴建航、魏潇天、王赛、舒福星、程图展、张铁、钱堃，共16人。其中，程图 展、张铁、钱堃为新增辅导人员。 | a gras | 限中文 | 节山版 | | --- | --- | --- | | 董军峰 | 廖小龙 | 黄亚颖 | | til) 9 - 2 - | 20132 | No to | | 胡家荣 | 谌泽昊 | ...

瞭望塔财经前言，一年内债务从527万飙升至4.05亿，增幅高达77倍。株洲科能却带着76%专科以下学历的员工队伍，试图闯关科创板。株洲科能的IPO申请 背后，隐藏着哪些与"科技"标签不相符的隐忧？ 瞭望塔财经获悉，2025年6月27日，株洲科能新材料股份有限公司（以下简称"株洲科能"）更新提交了2024年度财务数据，重新启动了其科创板IPO进程。这 已经是自2023年6月获受理以来，公司第四次因财务资料过期被迫中止。 瞭望塔财经通过招股书了解到，公司报告期内（2022-2024年）营收分别为6.79亿元、6.09亿元和7.87亿元，净利润分别为5082.30万元、4304.15万元和 7082.31万元。从表面看，业绩似乎在2024年有所回升，但深入分析财务数据和相关资料，会发现诸多令人担忧的问题。 一、股权代持与对赌协议，隐藏多年的控制权谜团 公司实际控制人赵科峰、唐燕夫妇有着一段长达14年的股权代持历史。2002年，赵、唐夫妇曾委托朋友陈尚荣、唐燕的舅舅李昌如代其夫妻二人持有科能有 限部分股份。 代持原因令人匪夷所思：赵、唐二人考虑到公司尚处于发展初期，后续将要持续加大资金投入，如仅以其夫妻二人名义全资持 ...

Group 1 - The company completed its IPO review on the Sci-Tech Innovation Board in just 88 days, making it the fastest company to pass this process this year [1] - Despite incurring losses exceeding 5 billion yuan over three years, the company attracted significant investment interest from 86 institutions, including major players like Mobile, Sequoia, and ByteDance [1] - The rapid IPO approval and strong institutional interest highlight the company's potential and the growing demand for GPU technology in various sectors [1]

| | | | | 首页 党建 发行上市 披露 监管 数据 产品 服务 规则 关于 | | | 一网通办 "三开门"专栏 | | --- | --- | --- | --- | --- | --- | --- | --- | | 发行上市 > 审核项目动态 > | | | | | | | | | 摩尔线程智能科技（北京）股份有限公司 科创版IPO | | | | | | | | | 已受更 2025-06-30 | | 已问询 2025-07-17 | 上市委会议 2025-09-26 | | | 提交注册 | 注册结果 | | | | | 通过 | | | | | | 项目基本信息 | | | | | | | | | 公司全称 | 摩尔线程智能科技（北京）股份有限公司 | | | 受理日期 | 2025-06-30 | | | | 公司简称 | 摩尔线程 | | | 融资金额(亿元) | 80.00 | | | | 审核状态 | 上市委会议通过 | | | 更新日期 | 2025-09-26 | | | | 保存机构 | 中信证券股份有限公司 | | | 保存代表人 | 周哲立吴霞娟 | | | | 会计师 ...

Core Points - The Shanghai Stock Exchange announced that Moore Threads plans to undergo review by the Sci-Tech Innovation Board on September 26 [1] - Several listed companies have responded regarding their cooperation with Moore Threads, indicating varying levels of investment and partnership [1][2] Group 1: Investment and Shareholding - Yuexiu Capital has identified Moore Threads as one of the investment projects of its industrial fund [1] - Xiamen Guomao holds a 0.67% stake in Moore Threads through an investment fund [1] - Wanhe Electric does not directly hold shares in Moore Threads but has a 0.4664% stake through a participating fund [1] - Heertai directly holds 1.0262% of Moore Threads [1] - Honglida indirectly holds approximately 0.3% of Moore Threads [1] - Chuling Information has an indirect holding of about 0.0229% in Moore Threads, which is minimal [1] Group 2: Business Cooperation - Zhuoyi Information has a client relationship with Moore Threads, but specific business cooperation details are confidential [1] - Kehua Data has initiated business cooperation with Moore Threads and other domestic GPU chip manufacturers [1] - Shenzhen Huqiang has established business cooperation with Moore Threads [1] Group 3: No Investment or Cooperation - Companies such as Juhua Technology, Jingxing Paper, and Sihui Tuxin have confirmed they do not hold shares in Moore Threads [2] - Many companies, including Dazhu CNC and Yiyaton, have stated they have no investment in Moore Threads [2] - Several companies, including Kabeiyi and Zhongke Chuangda, have reported no cooperation with Moore Threads [1][2]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to undergo its IPO review on September 24, 2025, after a two-year wait on the Sci-Tech Innovation Board, highlighting its progress in the biopharmaceutical sector and its innovative "Thousand Mice Ten Thousand Antibodies" program [1][4]. Group 1: Company Overview - Baiaosaitu was established in 2009 and operates as a preclinical CRO and biotechnology company, providing innovative animal models and drug development services based on its proprietary gene editing technology [1]. - The company has developed the RenMice platform, which allows for large-scale drug discovery targeting nearly a thousand potential drug targets [1]. Group 2: IPO Process and Financial Performance - The company was accepted for its Sci-Tech Innovation Board IPO on June 20, 2023, and has undergone two rounds of inquiries prior to the upcoming review [4]. - Financial data shows that Baiaosaitu's revenue increased from approximately 534 million yuan in 2022 to 980 million yuan in 2024, with a turnaround to a net profit of approximately 33.54 million yuan in 2024 after previous losses [5]. - In the first half of 2023, the company achieved a revenue of 621 million yuan, a 51.27% increase year-on-year, and reported a net profit of approximately 47.99 million yuan, indicating a successful recovery from losses [6]. Group 3: Research and Development Challenges - The company has experienced a significant reduction in its R&D personnel, with the number of dedicated R&D staff dropping from 58 in 2022 to just 5 in 2024, raising concerns about its innovation capacity [7]. - Governance issues are also present, as the major shareholders, who are a married couple, control over 27% of the voting rights, which may impact decision-making processes [7]. Group 4: Fundraising and Strategic Direction - Baiaosaitu has reduced its planned fundraising amount from 1.893 billion yuan to 1.185 billion yuan for its IPO, focusing on early drug development services, antibody drug research, and clinical projects [7][8]. - The company asserts that this reduction in fundraising will not alter its strategic direction, as the core projects will still revolve around its main business and technology platforms [8].

其三，要求发行人代表说明报告期股份支付会计处理是否符合企业会计准则规定。 其一，要求发行人代表结合产品结构、议价能力、市场开拓、主要产品验证及在手订单等情况，说明公 司是否存在毛利率持续下滑风险，以及经营业绩的可持续性。 其二，要求发行人代表说明 Jina Shaw、Ping Xu 及萍妮茹投资、蔡春生及一方建设之间是否存在应披露 未披露的关联关系或一致行动关系。结合实控人持股比例不高、实际控制公司时间较短、公司报告期多 次股权变动、历史上股东之间存在的分歧等情况，说明公司实控人的控制权是否稳定，是否存在上市后 控制权变更风险。 中经记者 孙汝祥 夏欣 实习生 王鑫 北京报道 上交所官网显示，9月19日，上交所上市审核委员会对厦门优迅芯片股份有限公司（以下简称"优迅股 份"）在科创板IPO进行审议，并作出暂缓审议的决定。 根据审议结果公告，上市委会议现场问询了三大问题。 需进一步落实事项为，发行人需说明报告期股份支付会计处理是否符合企业会计准则规定，保荐人和申 报会计师需发表明确核查意见。 （编辑：夏欣 审核：何莎莎 校对：燕郁霞） ...

9月19日晚间，上交所官网显示，厦门优迅芯片股份有限公司（以下简称"优迅股份"）科创板IPO当日上 会遭到暂缓审议。 招股书显示，优迅股份专注于光通信前端收发电芯片的研发、设计与销售。公司科创板IPO于2025年6 月26日获得受理，2025年7月15日进入问询阶段。此次冲击上市，优迅股份拟募集资金约8.09亿元，扣 除发行费用后，将用于下一代接入网及高速数据中心电芯片开发及产业化项目、车载电芯片研发及产业 化项目、800G及以上光通信电芯片与硅光组件研发项目。 除此之外，上市委要求优迅股份说明报告期股份支付会计处理是否符合企业会计准则规定。 （文章来源：北京商报） 在上市委会议现场，上市委要求优迅股份结合产品结构、议价能力、市场开拓、主要产品验证及在手订 单等情况，说明公司是否存在毛利率持续下滑风险，以及经营业绩的可持续性。 另外，上市委要求优迅股份说明JinaShaw、PingXu及萍妮茹投资、蔡春生及一方建设之间是否存在应披 露未披露的关联关系或一致行动关系。上市委还要求公司结合实控人持股比例不高、实际控制公司时间 较短、公司报告期多次股权变动、历史上股东之间存在的分歧等情况，说明公司实控人的控制权是否 ...

9月19日，上交所上市审核委发布公告称，厦门优迅芯片股份有限公司（简称"优迅股份"）科创板IPO暂 缓审议。 据招股书显示，优迅股份专注于光通信前端收发电芯片的研发、设计与销售。公司原计划募资8.89亿 元，冲刺科创板上市。 据了解，优迅股份IPO今年6月26日获受理，7月15日进入问询阶段，此后高效回复两轮问询后进入上会 程序。前期，公司市场空间及成长性、业绩增长可持续性、募投项目、离职员工转让等问题在审核问询 中被重点关注。 从今日的上市委现场问询来看，毛利率持续下滑风险、经营业绩的可持续性，以及实控人的控制权是否 稳定等被重点问询。同时，优迅股份收到一个需进一步落实事项。上市委要求公司说明报告期股份支付 会计处理是否符合企业会计准则规定。 具体来看，上交所要求优迅股份结合产品结构、议价能力、市场开拓、主要产品验证及在手订单等情 况，说明公司是否存在毛利率持续下滑风险，以及经营业绩的可持续性。并请保荐代表人发表明确意 见。 此外，控制权问题再次被监管关注。上交所要求公司说明Jina Shaw、Ping Xu及萍妮茹投资、蔡春生及 一方建设之间是否存在应披露未披露的关联关系或一致行动关系。同时，上交所要求公 ...

Core Viewpoint - Xiamen Youxun Chip Co., Ltd. (referred to as "Youxun") has had its IPO on the Sci-Tech Innovation Board postponed for review, raising concerns about its financial sustainability and governance structure [1][2] Group 1: Company Overview - Youxun focuses on the research, design, and sales of optical communication front-end transceiver chips [1] - The company aims to raise approximately 809 million yuan for the development and industrialization of next-generation access network and high-speed data center chips, automotive chips, and 800G and above optical communication chips and silicon photonic components [1] Group 2: IPO Review Concerns - The listing committee has requested Youxun to address potential risks related to declining gross margins, market expansion, and the sustainability of its operating performance [1] - The committee also inquired about undisclosed related party relationships among certain investors and the stability of the actual controller's control over the company, given the low shareholding ratio and historical ownership changes [1] Group 3: Accounting Compliance - Youxun is required to clarify whether its accounting treatment of share-based payments during the reporting period complies with the relevant accounting standards [2]